83_FR_827 83 FR 822 - Government-Owned Inventions; Availability for Licensing

83 FR 822 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 5 (January 8, 2018)

Page Range822-823
FR Document2018-00121

The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 83 Issue 5 (Monday, January 8, 2018) 
[Federal Register Volume 83, Number 5 (Monday, January 8, 2018)]
[Notices]
[Pages 822-823]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-00121]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Peter Tung, 240-669-5483; 
[email protected]. Licensing information and copies of the patent 
applications listed below may be obtained by communicating with the 
indicated licensing contact at the Technology Transfer and Intellectual 
Property Office, National Institute of Allergy and Infectious Diseases, 
5601 Fishers Lane, Rockville, MD, 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Compositions and Methods for Blocking Transmission of Plasmodium

    Description of Technology: According to the World Health 
Organization, about 3.2 billion people--nearly half of the world's 
population--are at risk of infection by Plasmodium parasites, resulting 
in malaria. An estimated 214 million cases and 438,000 deaths were due 
to malaria in 2015.
    P47 protein expressed by Plasmodium species allow malaria parasites 
to evade the mosquito immune system, thereby facilitating the 
transmission of malaria parasites. NIAID inventors have discovered the 
region of P47 protein responsible for the immune evasion function of 
this protein. Specific sequences of protein fragments of P47

[[Page 823]]

have proven to be both highly antigenic and shown to be responsible in 
allowing malaria parasites to evade the mosquito immune system. Proof 
of concept in a mouse model has demonstrated that vaccination using 
specific P47 protein fragments blocks Plasmodium transmission by 
mosquitoes.
    Immunization with the P47 protein variants of this technology 
provides a candidate for a potential, effective, transmission blocking 
malaria vaccine against Plasmodium species.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:

 Transmission blocking malaria vaccine

    Competitive Advantages:

 Transmission blocking of Plasmodium
 Transmission blocking activity based on recruiting the 
mosquito immune system to kill Plasmodium parasites by blocking 
Plasmodium immune evasion

    Development Stage:

 Early-stage
 In vitro data available
 In vivo data available (animal)

    Inventors: Carolina Veronica Barillas-Mury, Alvaro Molina-Cruz, 
Gaspar Exequiel Canepa, all of NIAID.
    Publications:
    Intellectual Property: HHS Reference No. E-294-2016/0--U.S. 
Provisional Application No. 62/463,011, filed February 24, 2017.
    Licensing Contact: Peter Tung, 240-669-5483; [email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize P47 protein fragments as a 
transmission blocking vaccine. For collaboration opportunities, please 
contact Peter Tung at 240-669-5483; [email protected].

    Dated: December 13, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-00121 Filed 1-5-18; 8:45 am]
 BILLING CODE 4140-01-P

822 Federal Register / Vol. 83, No. 5 / Monday, January 8, 2018 / Notices DEPARTMENT OF HEALTH AND under section 254b of the PHS Act. Of candidates from all groups and HUMAN SERVICES these 12, at least nine must be patient locations. members of health center governing Amy McNulty, Health Resources and Services boards who are familiar with the Administration Acting Director, Division of the Executive delivery of health care to migratory and Secretariat. seasonal agricultural workers. The National Advisory Council on Migrant [FR Doc. 2018–00096 Filed 1–5–18; 8:45 am] remaining three Council members must Health be individuals qualified by training and BILLING CODE 4165–15–P AGENCY: Health Resources and Services experience in the medical sciences or in Administration (HRSA), Department of the administration of health programs. DEPARTMENT OF HEALTH AND Health and Human Services (HHS). New members filling a vacancy that HUMAN SERVICES occurred prior to expiration of a term ACTION: Notice of request for may serve only for the remainder of National Institutes of Health nominations for voting members. such term. SUMMARY: HRSA is requesting Compensation: Members who are not Government-Owned Inventions; nominations to fill vacancies on the full-time federal employees shall be Availability for Licensing National Advisory Council on Migrant paid at the rate of $200 per day, including travel time plus per diem and AGENCY: National Institutes of Health, Health (NACMH). The NACMH is HHS. travel expenses in accordance with authorized and governed under the ACTION: Notice. Standard Government Travel Public Health Service (PHS) Act, as Regulations. amended. Specifically, HRSA is requesting SUMMARY: The invention listed below is DATES: The agency will receive nominations for: owned by an agency of the U.S. nominations on a continuous basis. Government and is available for Governing Board Members (8 licensing to achieve expeditious ADDRESSES: All nominations must be Vacancies) commercialization of results of submitted in hardcopy to the Designated federally-funded research and Federal Official (DFO), NACMH, Nominees must be members of a governing board of a migrant health development. Foreign patent Strategic Initiatives and Planning applications are filed on selected Division, Office of Policy and Program center or other entity assisted under section 330 of the PHS Act. Of the eight inventions to extend market coverage Development, Bureau of Primary Health for companies and may also be available Care, HRSA, 16N38B, 5600 Fishers board member vacancies, five nominees must also be patients of the entities they for licensing. Lane, Rockville, Maryland 20857. represent. (The Council has four current FOR FURTHER INFORMATION CONTACT: FOR FURTHER INFORMATION CONTACT: All board members who are patients.) Peter Tung, 240–669–5483; peter.tung@ requests for information regarding the Additionally, board member nominees nih.gov. Licensing information and NACMH nominations should be sent to must be familiar with the delivery of copies of the patent applications listed Esther Paul, DFO, NACMH, HRSA, in primary health care to migratory and below may be obtained by one of three ways: (1) Send a request to seasonal agricultural workers and their communicating with the indicated the following address: Esther Paul, families. licensing contact at the Technology Office of Policy and Program A complete nomination package Transfer and Intellectual Property Development, Bureau of Primary Health should include the following Office, National Institute of Allergy and Care, HRSA, 5600 Fishers Lane, information for each nominee: (1) A Infectious Diseases, 5601 Fishers Lane, 16N38B, Rockville, Maryland 20857; (2) NACMH nomination form; (2) three Rockville, MD, 20852; tel. 301–496– call (301) 594–4300; or (3) send an email letters of reference; (3) a statement of 2644. A signed Confidential Disclosure to epaul@hrsa.gov. prior service on the NACMH; and (4) a Agreement will be required to receive SUPPLEMENTARY INFORMATION: As biographical sketch of the nominee or a copies of unpublished patent authorized under section 217 of the PHS copy of his/her curriculum vitae. The applications. Act, as amended (42 U.S.C. 218), the nomination package must also state that SUPPLEMENTARY INFORMATION: Secretary established the NACMH. The the nominee is willing to serve as a Technology description follows. NACMH is governed by the Federal member of the NACMH and appears to Advisory Committee Act (5 U.S.C. have no conflict of interest that would Compositions and Methods for Blocking Appendix 2), which sets forth standards preclude membership. An ethics review Transmission of Plasmodium for the formation and use of advisory is conducted for each selected nominee. Description of Technology: According committees. Please contact Esther Paul at epaul@ to the World Health Organization, about The NACMH consults with and makes hrsa.gov and/or Carole Chamberlain at 3.2 billion people—nearly half of the recommendations to the HHS Secretary cchamberlain@hrsa.gov to obtain a world’s population—are at risk of and the HRSA Administrator nomination form. infection by Plasmodium parasites, concerning the organization, operation, HHS strives to ensure that the resulting in malaria. An estimated 214 selection, and funding of migrant health membership of HHS federal advisory million cases and 438,000 deaths were centers and other entities under grants committees is balanced in terms of due to malaria in 2015. and contracts under section 330 of the points of view represented, consistent P47 protein expressed by Plasmodium PHS Act (42 U.S.C. 254b). with the committee’s authorizing statute species allow malaria parasites to evade sradovich on DSK3GMQ082PROD with NOTICES The authorizing statute and the and charter. Appointment to the the mosquito immune system, thereby NACMH Charter require that the NACMH shall be made without facilitating the transmission of malaria Council consist of 15 members, each discrimination on the basis of age, race, parasites. NIAID inventors have serving a 4-year term. Twelve Council ethnicity, gender, sexual orientation, discovered the region of P47 protein members are required by statute to be disability, and cultural, religious, or responsible for the immune evasion governing board members of migrant socioeconomic status. The Department function of this protein. Specific health centers or other entities assisted encourages nominations of qualified sequences of protein fragments of P47 VerDate Sep<11>2014 16:29 Jan 05, 2018 Jkt 244001 PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 E:\FR\FM\08JAN1.SGM 08JAN1

Federal Register / Vol. 83, No. 5 / Monday, January 8, 2018 / Notices 823 have proven to be both highly antigenic DEPARTMENT OF HEALTH AND approaches in a regulatory context. Case and shown to be responsible in allowing HUMAN SERVICES studies will be presented to highlight malaria parasites to evade the mosquito where such techniques have been immune system. Proof of concept in a National Institutes of Health successfully applied both nationally and mouse model has demonstrated that internationally. The preliminary agenda vaccination using specific P47 protein Interagency Coordinating Committee and additional information about fragments blocks Plasmodium on the Validation of Alternative presentations will be posted at http:// transmission by mosquitoes. Methods Communities of Practice ntp.niehs.nih.gov/go/commprac-2018 as Webinar on Machine Learning in available. Immunization with the P47 protein Toxicology: Fundamentals of variants of this technology provides a Webinar and Registration: This Application and Interpretation; Notice webinar is open to the public with time candidate for a potential, effective, of Public Webinar; Registration transmission blocking malaria vaccine scheduled for questions by participants Information following each presentation. against Plasmodium species. AGENCY: National Institutes of Health, Registration for the webinar is required This technology is available for HHS. and is open through 2:30 p.m. on licensing for commercial development ACTION: Notice. January 23, 2018. Registration is in accordance with 35 U.S.C. 209 and 37 available at http://ntp.niehs.nih.gov/go/ CFR part 404, as well as for further SUMMARY: The Interagency Coordinating commprac-2018. Interested individuals development and evaluation under a Committee on the Validation of are encouraged to visit this web page to research collaboration. Alternative Methods (ICCVAM) stay abreast of the most current webinar Potential Commercial Applications: announces a public webinar ‘‘Machine information. Registrants will receive • Transmission blocking malaria Learning in Toxicology: Fundamentals instructions on how to access and vaccine of Application and Interpretation.’’ The participate in the webinar in an email webinar is organized on behalf of sent shortly before the webinar. Competitive Advantages: ICCVAM by the National Toxicology Individuals with disabilities who • Transmission blocking of Program Interagency Center for the need accommodation to participate in Plasmodium Evaluation of Alternative Toxicological this event should contact Elizabeth Methods (NICEATM). Interested persons Maull at phone: (984) 287–3157 or • Transmission blocking activity based may participate via WebEx. Time will email: maull@niehs.nih.gov. TTY users on recruiting the mosquito immune be allotted for questions from the should contact the Federal TTY Relay system to kill Plasmodium parasites audience. Service at (800) 877–8339. Requests by blocking Plasmodium immune should be made at least five business evasion DATES: Webinar: January 23, 2018, 1:00 days in advance of the event. p.m. to approximately 2:30 p.m. Eastern Development Stage: Background Information on ICCVAM Standard Time (EST). Registration for and NICEATM: ICCVAM is an • Early-stage the Webinar: December 18, 2017, until interagency committee composed of • In vitro data available 2:30 p.m. on January 23, 2018. representatives from 16 federal ADDRESSES: Webinar web page: http:// • In vivo data available (animal) regulatory and research agencies that ntp.niehs.nih.gov/go/commprac-2018. require, use, generate, or disseminate Inventors: Carolina Veronica Barillas- FOR FURTHER INFORMATION CONTACT: Dr. toxicological and safety testing Mury, Alvaro Molina-Cruz, Gaspar Warren Casey, Director, NICEATM; information. ICCVAM conducts Exequiel Canepa, all of NIAID. telephone: (984) 287–3118; email: technical evaluations of new, revised, Publications: warren.casey@nih.gov. and alternative safety testing methods Intellectual Property: HHS Reference SUPPLEMENTARY INFORMATION: and integrated testing strategies with No. E–294–2016/0—U.S. Provisional Background: ICCVAM promotes the regulatory applicability and promotes Application No. 62/463,011, filed development and validation of toxicity the scientific validation and regulatory February 24, 2017. testing methods that protect human acceptance of testing methods that more Licensing Contact: Peter Tung, 240– health and the environment while accurately assess the safety and hazards 669–5483; peter.tung@nih.gov. replacing, reducing, or refining animal of chemicals and products and replace, use. ICCVAM also provides guidance to reduce, or refine (enhance animal well- Collaborative Research Opportunity: being and lessen or avoid pain and test method developers and facilitates The National Institute of Allergy and distress) animal use. collaborations that promote the Infectious Diseases is seeking statements development of new test methods. To The ICCVAM Authorization Act of of capability or interest from parties address these goals, ICCVAM will hold 2000 (42 U.S.C. 285l–3) establishes interested in collaborative research to a Communities of Practice webinar on ICCVAM as a permanent interagency further develop, evaluate or ‘‘Machine Learning in Toxicology: committee of the National Institute of commercialize P47 protein fragments as Fundamentals of Application and Environmental Health Sciences and a transmission blocking vaccine. For Interpretation.’’ provides the authority for ICCVAM collaboration opportunities, please The ICCVAM webinar will explore involvement in activities relevant to the contact Peter Tung at 240–669–5483; the fundamentals of machine learning development of alternative test peter.tung@nih.gov. approaches, including how they work, methods. ICCVAM acts to ensure that sradovich on DSK3GMQ082PROD with NOTICES Dated: December 13, 2017. how they are interpreted, and new and revised test methods are Suzanne Frisbie, precautions that should be taken when validated to meet the needs of federal Deputy Director, Technology Transfer and evaluating their output. It will feature agencies, increase the efficiency and Intellectual Property Office, National Institute presentations by two experts in use of effectiveness of federal agency test of Allergy and Infectious Diseases. machine learning in toxicity texting method review, and optimize utilization [FR Doc. 2018–00121 Filed 1–5–18; 8:45 am] applications that will address issues of scientific expertise outside the federal BILLING CODE 4140–01–P specific to use of machine learning government. Additional information VerDate Sep<11>2014 16:29 Jan 05, 2018 Jkt 244001 PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 E:\FR\FM\08JAN1.SGM 08JAN1


Document Created: 2018-01-06 02:32:02
Document Modified: 2018-01-06 02:32:02
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactPeter Tung, 240-669-5483; [email protected] Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
FR Citation83 FR 822 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR